文献速递消化系统肿瘤

吉西他滨联合白蛋白紫杉醇及S-1三药化疗在晚期胰腺癌中实现高缓解率和转化率:多中心II期研究

Triplet chemotherapy with Gemcitabine, Nab-paclitaxel, and S-1 achieves high response and conversion rates in advanced pancreatic cancer: A multicenter phase II study (GeNeS1S trial).
PubMed 文献 · Eur J Cancer · 2026-09-10

该多中心单臂II期研究评估S-1联合吉西他滨及白蛋白紫杉醇方案治疗初治晚期胰腺癌的疗效与安全性,主要终点客观缓解率(ORR)达63.3%(95%CI 45.5-78.2),疾病控制率86.7%,中位无进展生存期9.0个月、总生存期15.0个月,局部晚期亚组ORR为100.0%且5例中3例(60.0%)成功转化手术。

要点

  • 三药方案ORR 63.3%,中位PFS 9.0个月、OS 15.0个月。
  • 局部晚期亚组ORR 100.0%,60.0%患者实现转化手术。
  • 主要≥3级不良事件为血液学毒性,中性粒细胞减少43.3%,无治疗相关死亡。

核心结论

  • 在吉西他滨联合白蛋白紫杉醇基础上加用S-1显示出高抗肿瘤活性、持久疾病控制和令人鼓舞的转化切除率,支持进一步评估该方案,尤其针对交界可切除或局部晚期胰腺癌。

研究设计与样本

  • 多中心、单臂、II期研究,纳入30例既往未治疗的局部晚期、复发或转移性胰腺癌患者。
  • 治疗方案为吉西他滨600 mg/m²和白蛋白紫杉醇90 mg/m²第1、8天,联合口服S-1(按体表面积50/70/80 mg/日)第1-14天,每3周为一周期。
  • 主要终点为客观缓解率(ORR),次要终点包括疾病控制率(DCR)、无进展生存期(PFS)、总生存期(OS)、缓解持续时间(DoR)、原发肿瘤缓解、转化率和安全性。

主要发现

  • 2018年9月至2024年4月共入组30例患者,ORR为63.3%(95%CI 45.5-78.2),达到预设主要终点。
  • 仅6.7%患者出现疾病进展,DCR为86.7%。
  • 中位PFS为9.0个月(95%CI 7.5-10.5),中位OS为15.0个月(95%CI 12.6-17.4),中位DoR为8.6个月(95%CI 4.7-12.5)。
  • 局部晚期疾病患者ORR为100.0%,5例中3例(60.0%)接受转化手术。
  • ≥3级不良事件主要为血液学毒性,包括中性粒细胞减少(43.3%)、厌食(6.7%)和胆道感染(6.7%),无治疗相关死亡。

临床怎么用

  • 该三药方案在晚期胰腺癌中显示出较高缓解率和转化潜力,尤其局部晚期患者可考虑用于转化治疗探索。
  • 治疗期间需重点监测血液学毒性,中性粒细胞减少发生率较高。

局限性

  • 单臂II期研究,样本量仅30例,缺乏随机对照。
  • 局部晚期亚组仅5例,转化率结果需更大样本验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: S-1 has demonstrated non-inferiority to gemcitabine (GEM) in overall survival (OS) in advanced pancreatic cancer and superiority in the adjuvant setting for resectable disease. This study evaluated the efficacy and safety of S-1 combined with GEM plus nab-paclitaxel (nPTX) in advanced pancreatic cancer. METHODS: This multicenter, single-arm, phase II study enrolled patients with previously untreated locally advanced, recurrent, or metastatic pancreatic cancer. Treatment consisted of GEM (600 mg/m²) and nPTX (90 mg/m²) on days 1 and 8 plus oral S-1 (50/70/80 mg/day according to body surface area) on days 1-14 of a 3-week cycle. The primary endpoint was objective response rate (ORR). Secondary endpoints included disease control rate (DCR), progression-free survival (PFS), OS, duration of response (DoR), primary tumor response, conversion rate, and safety. RESULTS: Between September 2018 and April 2024, 30 patients were enrolled. ORR was 63.3% (95% CI, 45.5-78.2), meeting the prespecified primary endpoint. PD was observed in only 6.7% of patients, resulting in a DCR of 86.7%. Median PFS and OS were 9.0 (95% CI, 7.5-10.5) and 15.0 months (12.6-17.4), respectively, and median DoR was 8.6 months (95% CI, 4.7-12.5). In locally advanced disease, ORR was 100.0%, and three of five patients (60.0%) underwent conversion surgery. Grade ≥ 3 adverse events were mainly hematologic, including neutropenia (43.3%), anorexia (6.7%), and biliary tract infection (6.7%), with no treatment-related deaths. CONCLUSION: The addition of S-1 to GEM plus nPTX demonstrated high antitumor activity, durable disease control, and encouraging conversion to resection, supporting further evaluation of this regimen, particularly in borderline resectable or locally advanced pancreatic cancer.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Nagatani Y, Chayahara N, Satake H, et al. Triplet chemotherapy with Gemcitabine, Nab-paclitaxel, and S-1 achieves high response and conversion rates in advanced pancreatic cancer: A multicenter phase II study (GeNeS1S trial). Eur J Cancer. 2026. PMID: 42748587. doi:10.1016/j.ejca.2026.117034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。